Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
批准号:
10669605
负责人:
Jeremy Michael Stark
金额:
$39.45万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30
关键词:
AddressBindingBiological AssayBiological MarkersCellsChromosomal BreaksChromosomesClinical TrialsCodeCombined Modality TherapyComplexDNADNA DamageDNA Double Strand BreakDNA biosynthesisDNA replication forkDNA-PKcsDNA-dependent protein kinaseDataDefectDouble Strand Break RepairEnsureEventG22P1 geneGeneticGenomeGenome StabilityGenomic InstabilityHumanIonizing radiationLaboratoriesLasersLigaseMagnetic Resonance ImagingMaintenanceMeasuresMediatingMissionModelingMutationNonhomologous DNA End JoiningOutcomePRKDC genePTEN genePathway interactionsPatient-Focused OutcomesPhosphotransferasesPlayPoly(ADP-ribose) Polymerase InhibitorRNA ProcessingRadiation therapyRegulationReportingResistanceRibosomal RNARoleSeriesSignal TransductionSiteTechnologyTestingTimeTreatment ProtocolsTreatment outcomeTumor Suppressor ProteinsUnited States National Institutes of HealthV(D)J RecombinationXRCC4 geneXRCC5 genebiomarker developmentcancer cellcancer therapyclastogencofactorexperimental studyimprovedinhibitorinnovationinsertion/deletion mutationinsightkinase inhibitormutantnovelnucleaseradiation resistancerecruitrepairedreplication stressresponseresponse biomarkerscaffoldsynergismtherapeutic targettreatment strategytumor
中文摘要
摘要靶向DNA依赖性蛋白激酶(DNAPKcs)催化亚基的激酶抑制剂
正在开发使肿瘤对致染色体断裂剂(染色体断裂)如放射疗法敏感。
DNAPKcs激酶抑制剂M3814(EMD Serono)正在进行临床试验,其他新的有效抑制剂已经
被举报。阐明DNAPKcs在染色体断裂修复中的作用是重要的,因为它将
能够识别其中的背景(例如肿瘤遗传背景和治疗方案),
DNAPKcs激酶抑制剂是最有效的,从而开发生物标志物来预测肿瘤反应。
长期以来,DNAPKcs被认为对促进辐射抗性是重要的,但其在染色体上的作用,
断裂修复仍然是难以捉摸的。也就是说,DNAPKcs与典型的非同源的
DNA双链断裂(DSB)修复的末端连接(C-NHEJ)途径,但不是所有C-NHEJ都需要
事件(例如,对于V(D)J重组信号EJ而言,在很大程度上是不确定的)。此外,直到最近,
检测染色体DSB的C-NHEJ的测定法,除了V(D)J重组,还没有可用的,由于
与替代EJ(ALT-EJ)途径部分冗余。为了解决这一技术差距,我们的实验室
最近发现了C-NHEJ的一个特殊标志。也就是说,我们报道了几种C-NHEJ因子(即XLF,
KU 70和XRCC 4)是平端DSB(由Cas9核酸酶诱导)之间的EJ所需的,所述平端DSB是
连接而不引起插入/缺失突变(indel),即准确/无Indel EJ。根据初步数据,我们
显示DNAPKcs是No Indel EJ部分所需的,但其作用在具有XLF的细胞中显著放大
功能降低突变(亚型),包括对KU结合重要的XLF基序突变
异二聚体和DNA。基于这些发现,我们将确定DNAPKcs在染色体EJ中的作用,
断裂剂抗性在目标1中,我们假设XLF和DNAPKcs协同作用,以确保NO
Indel EJ,并且这种协同作用对于断裂剂抗性是至关重要的。我们还将研究这些因素之间的相互作用
DNA复制中的两个因素,并定义了XLF和DNAPKcs的关键结构域,这两个结构域对每一个都很重要。
功能协调发展的在目标2中,我们研究了DNAPKcs和一组KU结合因子之间的相互作用,以及
ALT-EJ,关于断裂剂抗性和基因组稳定性。我们测试DNAPKcs是否协同作用,
仅用XLF,但也用四种KU结合因子(CYREN/MRI、PAXX、APLF和WRN)中的每一种,用于无插入缺失
EJ、断裂剂抗性和KU对DNA损伤的强募集。这些研究将填补我们的一个主要空白,
了解C-NHEJ机制。最后,我们证实了DNAPKcs和ALT-EJ的联合破坏,
导致异常的DSB末端加工,导致大的缺失,和/或持久的未修复的DSB,从而
导致克隆形成存活率降低和/或断裂原致敏。总之,我们将测试整体
假设DNAPKcs促进准确的EJ(即无插入缺失EJ),其在这种EJ中的作用被缺陷放大
在一组KU结合因子中,并且它对于ALT-EJ缺陷细胞中的基因组稳定性至关重要。
英文摘要
SUMMARY. Kinase inhibitors targeting the catalytic subunit of the DNA-dependent protein kinase (DNAPKcs)
are being developed to sensitize tumors to clastogenic (chromosomal-breaking) agents, such as radiotherapy.
The DNAPKcs kinase inhibitor M3814 (EMD Serono) is in clinical trials, and other new potent inhibitors have
been reported. Elucidating the role of DNAPKcs in the repair of chromosomal breaks is significant because it will
enable the identification of the contexts (e.g. tumor genetic background and treatment regimens) in which
DNAPKcs kinase inhibitors are most effective, and thereby develop biomarkers to predict tumor response.
DNAPKcs has long been recognized as important for promoting radioresistance, but its role in chromosomal
break repair has remained elusive. Namely, DNAPKcs associates with factors in the canonical non-homologous
end joining (C-NHEJ) pathway for DNA double-strand break (DSB) repair but is not required for all C-NHEJ
events (e.g. is largely dispensable for V(D)J recombination signal EJ). Furthermore, until recently, specific
assays to detect C-NHEJ of chromosomal DSBs, apart from V(D)J recombination, have not been available, due
to partial redundancy with the alternative EJ (ALT-EJ) pathway. To address this gap in technology, our laboratory
recently identified a specific hallmark of C-NHEJ. Namely, we reported that several C-NHEJ factors (i.e. XLF,
KU70, and XRCC4) are required for EJ between blunt-ended DSBs (induced by the Cas9 nuclease) that are
joined without causing insertion/deletion mutations (indels), i.e. for accurate/No Indel EJ. In preliminary data, we
show that DNAPKcs is partially required for No Indel EJ, but its role is substantially magnified in cells with XLF
reduced-function mutations (hypomorphs), including mutations in an XLF motif important for binding the KU
heterodimer and DNA. Building on these findings, we will define the role of DNAPKcs in chromosomal EJ and
clastogen resistance. In Aim 1, we hypothesize that XLF and DNAPKcs function synergistically to ensure No
Indel EJ, and this synergy is critical for clastogen resistance. We will also examine the interplay between these
two factors in DNA replication, and define the key domains of XLF and DNAPKcs important for each of these
functions. In Aim 2, we investigate the interplay between DNAPKcs and a set of KU-binding factors, as well as
ALT-EJ, on clastogen resistance and genome stability. We test whether DNAPKcs functions synergistically not
only with XLF, but also with each of four KU-binding factors (CYREN/MRI, PAXX, APLF, and WRN), for No Indel
EJ, clastogen resistance, and robust recruitment of KU to DNA damage. These studies will fill a major gap in our
understanding of C-NHEJ mechanisms. Finally, we posit that combined disruption of DNAPKcs and ALT-EJ
causes aberrant DSB end processing, leading to large deletions, and/or persistent, unrepaired DSBs, thereby
causing reduced clonogenic survival and/or clastogen sensitization. In summary, we will test the overall
hypothesis that DNAPKcs promotes accurate EJ (i.e. No Indel EJ), that its role in such EJ is magnified by defects
in a set of KU-binding factors, and that it is critical for genome stability in cells deficient in ALT-EJ.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
-
批准号:10415198
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2021
-
负责人:Jeremy Michael Stark
-
依托单位:
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
-
批准号:10296356
-
项目类别:
-
资助金额:$40.26万
-
财政年份:2021
-
负责人:Jeremy Michael Stark
-
依托单位:
The role of O-GlcNAcylation in DNA damage repair and cancer therapy
-
批准号:10650718
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Jeremy Michael Stark
-
依托单位:
The role of O-GlcNAcylation in DNA damage repair and cancer therapy
-
批准号:10171810
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2019
-
负责人:Jeremy Michael Stark
-
依托单位:
The role of O-GlcNAcylation in DNA damage repair and cancer therapy
-
批准号:10399545
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Jeremy Michael Stark
-
依托单位:
Regulation of Single Strand Annealing Repair of Mammalian Chromosomal Breaks
-
批准号:9236171
-
项目类别:
-
资助金额:$38.89万
-
财政年份:2016
-
负责人:Jeremy Michael Stark
-
依托单位:
Regulation of Single Strand Annealing Repair of Mammalian Chromosomal Breaks
-
批准号:9901462
-
项目类别:
-
资助金额:$38.89万
-
财政年份:2016
-
负责人:Jeremy Michael Stark
-
依托单位:
THE MECHANISM OF RECOMBINATION-MEDIATED LOSS OF HETEROZYGOSITY IN HUMAN
-
批准号:7382140
-
项目类别:
-
资助金额:$21.12万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7895013
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7658248
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8676686
-
项目类别:
-
资助金额:$21.05万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8370791
-
项目类别:
-
资助金额:$21.7万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7279126
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7085607
-
项目类别:
-
资助金额:$22.48万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8765425
-
项目类别:
-
资助金额:$7.33万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7478540
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:9066590
-
项目类别:
-
资助金额:$21.7万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8507612
-
项目类别:
-
资助金额:$20.39万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Analytical Cytometry Core
-
批准号:10328520
-
项目类别:
-
资助金额:$8.85万
-
财政年份:1997
-
负责人:Jeremy Michael Stark
-
依托单位:
Analytical Cytometry
-
批准号:10628585
-
项目类别:
-
资助金额:$5.62万
-
财政年份:1997
-
负责人:Jeremy Michael Stark
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: